GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Short Interest

Vicore Pharma Holding AB (OSTO:VICO BTA) Short Interest


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Vicore Pharma Holding AB's Short Interest

For the Biotechnology subindustry, Vicore Pharma Holding AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Short Interest falls into.


;
;

Vicore Pharma Holding AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Short Interest
Comparable Companies
OSTO:HNSA OSTO:GENO OSTO:XSPRAY OSTO:EGTX OSTO:SANION OSTO:BINV OSTO:DMYD B OSTO:SYNACT XSAT:HAMLET B OSTO:IBT B VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
VICO:Sweden
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Website
https://www.vicorepharma.com
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines